In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Single nuclear polymorphism a1166c of agtiir1 gene and cardiac remodeling after st segment elevation myocardial infarction

Session Poster Session 3

Speaker Associate Professor Irina Vishnevskaya

Event : Heart Failure 2018

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease – Pathophysiology and Mechanisms
  • Session type : Poster Session

Authors : OV Petyunina (Kharkiv,UA), MP Kopytsya (Kharkiv,UA), IR Vyshnevska (Kharkiv,UA)

Authors:
OV Petyunina1 , MP Kopytsya1 , IR Vyshnevska1 , 1Government institution“L.T. Malaya Therapy National institute of the National academy of medical sci - Kharkiv - Ukraine ,

Citation:

Purpose. To perform medical-genetic analysis of dynamic of structural and functional myocardial parameters, heart rate variability data depending on polymorphism ?1166? of R1 receptor of angiotensin II (AGTIIR1) gene in patients with myocardial infarction with ST segment elevation - STEMI.

Matherials and methods. 87 patients with STEMI, 70 (80%) male and 17 (20%) female at average age (58,94±10,16) years were examined. Patients were hospitalized during first three days after selective coronary angiography and infarct-related artery stenting were performed. After 6-month observation period  patients were reexamined. Allele polymorphism A1166C of AGTIIR1 gene was determined by polymerase chain reaction in real time, heart rate variability (HRV) – Cholter 24-hour monitoring, morpho-functional data – ultrasound research.

Results and discussion. In patients with ??+??-genotypes compared with ?? on 1-3 day of STEMI higher level of  left ventricular (LV) end diastolic diameter (EDD) (?=0,004), LV end systolic diameter (ESD) (?=0,043), LV myocardial mass (MM) (?=0,041), frequency of mitral regurgitation (?=0,028), the tendency to higher LV end diastolic volume (EDV) (?=0,089) were revealed. These means unfavorable structure of early after infarction myocardial remodeling (RM). After 6 month patients with ??+??- genotypes compared with ?? demonstrated higher LVEDD (?=0,083), left atrium (?=0,091), LVMM (?=0,081). When analysed echocardiographic data in acute period of STEMI and after 6-month observation, groups with ?? and ??+??-genotypes demonstrated significant or tendency to higher level of LVEDV (?=0,06, ?=0,034), LVEDD (?=0,057, ?=0,01), LV ejection fraction (EF) (?=0,037, ?=0,07) respectevly. In patients with AC+CC-genotypes compared with AA were lower level of SDNN (P=0,049), HF (?=0,053), higher level of  LF (P=0,069) and LF/HF-index (P=0,046).

Conclusions. Polymorphic ??+??-genotype cariers compared with ??-genotype of AGTIIR1 gene demonstrated more relevant increase of left ventricular diameters and volume, left atrium and LV myocardial mass in acute period of STEMI. After 6-month period in both groups LV dilatation and LVEF were observed. These data refer to the similar with Frank-Starling law dynamic of compensation. Patients with ??+??-genotypes compared with A? demonstrated unfavorable structure of LV CR and associates with more expressed sympathic-vagous dysbalance.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are